US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

F/m Emerald Life Sciences Innovation ETF

42.61

+0.93212.24%

Post-market: 42.680.0729+0.17%16:10 EDT

Volume:561

Turnover:23.88K

Market Cap:118.32M

PE:- -

High:42.68

Open:42.52

Low:42.52

Close:41.68

52wk High:48.78

52wk Low:29.44

Shares:2.78M

Float Shares:2.78M

Volume Ratio:0.36

T/O Rate:0.02%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock

THOMSON REUTERS

Spyre Therapeutics - Prices Public Offering of 4,117,648 Shares at $85 Per Share

THOMSON REUTERS

Spyre Therapeutics Launches Underwritten Public Offering of Common Stock

Spyre Therapeutics - Net Proceeds Intended for Advancing Programs and Spy072 Late-Stage Development

THOMSON REUTERS

Spyre Therapeutics Announces Proposed Public Offering of Its Common Stock

THOMSON REUTERS

Guardant Health reports COSMOS study published in Cancer Research Communications

Guardant Health Cosmos-MEL01 Study Shows Guardant Reveal Detects 81% of Distant Melanoma Recurrences

Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly

Spyre Therapeutics CFO Scott L. Burrows Disposes of USD 1.85 Million in Common Shares

Spyre Therapeutics Grants Inducement Equity Awards of 21,424 Stock Options and 6,604 RSUs to New Hires

Spyre Therapeutics Announces Grants of Inducement Awards

Travere Therapeutics announces FILSPARI data presentations at ASN Kidney Week

Travere Says Phase 2 Spartan Final Analysis Shows 75% Complete Proteinuria Remission with Filspari in IgA Nephropathy

Veeva supporting transformation of medicine through AI, Barron’s reports

Guardant Health price target raised to $200 from $190 at Guggenheim

Spyre Therapeutics Inc : Jonestrading Raises Target Price to $130 from $121

THOMSON REUTERS

Arovella Nears First Patient Dosing in Pivotal ALA-101 Cell Therapy Trial

Spyre Therapeutics Shares up 6.4% After Merck's Experimental Drug Succeeds in Skin Disease Trial

THOMSON REUTERS

Spyre Gains After Merck's Drug Succeeds in Skin Disease Trial

MiNK selected for ARPA-H-Funded initiative to advance room-temp cell therapy

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/stock/LFSC/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"LFSC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","market":"US","secType":"STK","nameCN":"F/m Emerald Life Sciences Innovation ETF","latestPrice":42.6071,"timestamp":1791576000000,"preClose":41.675,"halted":0,"volume":561,"hourTrading":{"tag":"盘后","latestPrice":42.68,"preClose":42.6071,"latestTime":"16:10 EDT","volume":1,"amount":42.6071,"timestamp":1791576604081,"change":0.0729,"changeRate":0.001711,"amplitude":0},"delay":0,"changeRate":0.022365926814637206,"floatShares":2777035,"shares":2777035,"eps":0,"marketStatus":"Market Closed","change":0.9321,"latestTime":"10-09 16:00:00 EDT","open":42.515,"high":42.68,"low":42.515,"amount":23883,"amplitude":0.003959,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791792000000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":41.675,"sharesOutstanding":2657035,"nav":41.68,"aum":115746818.8,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":42.68,"preClose":42.6071,"latestTime":"16:10 EDT","volume":1,"amount":42.6071,"timestamp":1791576604081,"change":0.0729,"changeRate":0.001711,"amplitude":0},"volumeRatio":0.35855808645794174},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","floatShares":2777035,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.35855808645794174,"shares":2777035,"dividePrice":0,"high":42.68,"amplitude":0.003959,"preClose":41.675,"low":42.515,"week52Low":29.4441,"pbRate":"--","week52High":48.78,"institutionHeld":0,"latestPrice":42.6071,"eps":0,"divideRate":0,"volume":561,"delay":0,"ttmEps":0,"open":42.515,"prevYearClose":36.6147,"prevWeekClose":43.401,"prevMonthClose":44.5697,"prevQuarterClose":44.5697,"fiveDayClose":43.401,"twentyDayClose":45.3275,"sixtyDayClose":44.9054},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LFSC\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LFSC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LFSC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LFSC\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2673080688","title":"Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2673080688","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673080688?lang=en_us&edition=fundamental","pubTime":"2026-10-06 08:13","pubTimestamp":1791245636,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nTUA6MQ6PV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SYRE","LFSC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673080684","title":"Spyre Therapeutics - Prices Public Offering of 4,117,648 Shares at $85 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2673080684","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673080684?lang=en_us&edition=fundamental","pubTime":"2026-10-06 08:13","pubTimestamp":1791245636,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nTUA6MQ6PV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SYRE","BK4139","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673081433","title":"Spyre Therapeutics Launches Underwritten Public Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2673081433","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673081433?lang=en_us&edition=fundamental","pubTime":"2026-10-06 04:01","pubTimestamp":1791230497,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics launches underwritten public offering of common stockSpyre Therapeutics launched an underwritten public offering of common stock.Underwriters receive a 30-day option to buy up to 15","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nNDLb20fV5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4207","NDAQ","IE00BN0W2T93.GBP","IE00BQXX3D17.EUR","IE00B64PRP62.GBP","BK4127","SG9999014039.USD","LFSC","LU2210150020.SGD","SYRE","SF","SG9999014021.USD","IE00BN0W2V16.EUR","BK4139","IE00BKPKM429.USD","SG9999014005.SGD","IE00BQXX3C00.GBP","LU0314104364.USD","SG9999014013.SGD","IE00BQXX3F31.USD","IE00B3QW5Z07.USD","LU2210149790.SGD","BK4112","IE00BGHQF748.EUR","LU2095319765.USD","MNSH","BK4588","IE00BN0W2W23.USD","BK4585","BCDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673100081","title":"Spyre Therapeutics - Net Proceeds Intended for Advancing Programs and Spy072 Late-Stage Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2673100081","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673100081?lang=en_us&edition=fundamental","pubTime":"2026-10-06 04:01","pubTimestamp":1791230460,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nTUA13QSRF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SYRE","BK4139","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673081483","title":"Spyre Therapeutics Announces Proposed Public Offering of Its Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2673081483","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673081483?lang=en_us&edition=fundamental","pubTime":"2026-10-06 04:01","pubTimestamp":1791230460,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nTUA13QSRF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SYRE","BK4139","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673085570","title":"Guardant Health reports COSMOS study published in Cancer Research Communications","url":"https://stock-news.laohu8.com/highlight/detail?id=2673085570","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673085570?lang=en_us&edition=fundamental","pubTime":"2026-10-05 23:30","pubTimestamp":1791214209,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) announced Cancer Research Communications, a journal of the American Association for Cancer Research, has published results fro...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/guardant-health-reports-cosmos-study-published-in-cancer-research-communications-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/guardant-health-reports-cosmos-study-published-in-cancer-research-communications-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4196","BK4588","GDOC","BK4551","EKG","PTH","BK4535","GNOM","GNMX","LFSC","LU0109394709.USD","LU0889565916.HKD","GH","LU0320765992.SGD","BK4585","FFOX","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673085807","title":"Guardant Health Cosmos-MEL01 Study Shows Guardant Reveal Detects 81% of Distant Melanoma Recurrences","url":"https://stock-news.laohu8.com/highlight/detail?id=2673085807","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673085807?lang=en_us&edition=fundamental","pubTime":"2026-10-05 23:27","pubTimestamp":1791214069,"startTime":"0","endTime":"0","summary":"Guardant Health COSMOS-MEL01 study shows Guardant Reveal detects 81% of distant melanoma recurrencesGuardant Health disclosed published results from a prospective, multicenter COSMOS study evaluating ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nNDL5cqdWm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LFSC","GNMX","BK4535","GH","BK4196","GDOC","BK4585","EKG","FFOX","GNOM","PTH","BK4588","BK4551","LU0320765992.SGD","LU0109394709.USD","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673702771","title":"Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly","url":"https://stock-news.laohu8.com/highlight/detail?id=2673702771","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673702771?lang=en_us&edition=fundamental","pubTime":"2026-10-05 20:00","pubTimestamp":1791201600,"startTime":"0","endTime":"0","summary":"Trial follows promising MAR002 Phase 1 clinical trial results that demonstrated deep and durable IGF-1 suppression with PK properties that may enable dosing as infrequently as once every two weeks, co","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/05/3374474/18623/en/marea-therapeutics-a-subsidiary-of-lisata-therapeutics-announces-first-patient-dosed-in-phase-2-clinical-trial-of-mar002-a-potential-best-in-disease-investigational-therapy-for-the.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4535","ENDO","BK4551","KBWY","GNOM","PTH","LU0889565916.HKD","LU0320765992.SGD","PK","BK4585","GH","BK4007","EKG","HELX","LENZ","FFOX","BK4588","BK4196","LFSC","LU0109394709.USD","BK4218","BK4181","BK4183","GNMX","GDOC","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672995742","title":"Spyre Therapeutics CFO Scott L. Burrows Disposes of USD 1.85 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2672995742","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672995742?lang=en_us&edition=fundamental","pubTime":"2026-10-03 09:30","pubTimestamp":1790991008,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics CFO Scott L. Burrows disposes of USD 1.85 million in common sharesSpyre Therapeutics CFO Scott L. Burrows cut his direct stake to 79,762 common shares.Sold 17,500 shares on Sep. 30 ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261003:nNDLbqQ1FS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Spyre Therapeutics CFO Scott L. Burrows Disposes of USD 1.85 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672746038","title":"Spyre Therapeutics Grants Inducement Equity Awards of 21,424 Stock Options and 6,604 RSUs to New Hires","url":"https://stock-news.laohu8.com/highlight/detail?id=2672746038","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672746038?lang=en_us&edition=fundamental","pubTime":"2026-10-03 04:05","pubTimestamp":1790971539,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics grants inducement equity awards of 21,424 stock options and 6,604 RSUs to new hiresSpyre Therapeutics granted inducement equity awards to two non-executive employees under its 2018 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nNDL2fh2L7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","IE00BN0W2V16.EUR","IE00BQXX3D17.EUR","IE00BN0W2T93.GBP","LU0314104364.USD","SG9999014005.SGD","BK4588","SG9999014021.USD","IE00BGHQF748.EUR","SG9999014039.USD","IE00BKPKM429.USD","LFSC","BK4585","LU2095319765.USD","BK4112","BK4139","IE00B64PRP62.GBP","SYRE","IE00BN0W2W23.USD","SG9999014013.SGD","IE00BQXX3C00.GBP","IE00B3QW5Z07.USD","NDAQ","IE00BQXX3F31.USD","LU2210149790.SGD","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672749945","title":"Spyre Therapeutics Announces Grants of Inducement Awards","url":"https://stock-news.laohu8.com/highlight/detail?id=2672749945","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672749945?lang=en_us&edition=fundamental","pubTime":"2026-10-03 04:05","pubTimestamp":1790971500,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Oct.  02, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/02/3374024/0/en/spyre-therapeutics-announces-grants-of-inducement-awards.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","SYRE","LENZ","BK4139","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672971031","title":"Travere Therapeutics announces FILSPARI data presentations at ASN Kidney Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2672971031","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672971031?lang=en_us&edition=fundamental","pubTime":"2026-10-02 22:05","pubTimestamp":1790949928,"startTime":"0","endTime":"0","summary":"Travere Therapeutics (TVTX) will share nine new data presentations, including five oral presentations, at the American Society of Nephrology Kidney...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/travere-therapeutics-announces-filspari-data-presentations-at-asn-kidney-week-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/travere-therapeutics-announces-filspari-data-presentations-at-asn-kidney-week-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","FFTY","LFSC","BK4539","LU2324357040.USD","BK4139","TVTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672071710","title":"Travere Says Phase 2 Spartan Final Analysis Shows 75% Complete Proteinuria Remission with Filspari in IgA Nephropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2672071710","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672071710?lang=en_us&edition=fundamental","pubTime":"2026-10-02 22:00","pubTimestamp":1790949647,"startTime":"0","endTime":"0","summary":"Travere says Phase 2 SPARTAN final analysis shows 75% complete proteinuria remission with FILSPARI in IgA nephropathyTravere Therapeutics flagged nine new data presentations on FILSPARI for IgA nephro","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nNDLbtFSRV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVTX","BK4139","LU2324357040.USD","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672579387","title":"Veeva supporting transformation of medicine through AI, Barron’s reports","url":"https://stock-news.laohu8.com/highlight/detail?id=2672579387","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672579387?lang=en_us&edition=fundamental","pubTime":"2026-10-01 20:55","pubTimestamp":1790859332,"startTime":"0","endTime":"0","summary":"AI holds the promise to accelerate drug development, optimize clinical trials, and bring lifesaving therapies to market faster, and Veeva (VEEV) Sy...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/veeva-supporting-transformation-of-medicine-through-ai-barrons-reports-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/veeva-supporting-transformation-of-medicine-through-ai-barrons-reports-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CHAT","MEDX","LU0170899867.USD","BK4528","BK4585","IDNA","LGHT","ARTY","LU1989764748.USD","GDOC","AIPO","LU0266013472.USD","NVIB","VEEV","EKG","BK4613","HYLG","LU1989764664.SGD","LU0058720904.USD","LU0106261372.USD","BK4534","BK4588","QTOC","LU0289739699.SGD","VTHR","BMED","BK4167","AGIX","LU0006306889.USD","BK4504","LFSC","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672520357","title":"Guardant Health price target raised to $200 from $190 at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2672520357","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672520357?lang=en_us&edition=fundamental","pubTime":"2026-10-01 20:37","pubTimestamp":1790858259,"startTime":"0","endTime":"0","summary":"Guggenheim raised the firm’s price target on Guardant Health (GH) to $200 from $190 and keeps a Buy rating on the shares. The firm adjusted its mod...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/guardant-health-price-target-raised-to-200-from-190-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/guardant-health-price-target-raised-to-200-from-190-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LFSC","GNOM","LU0889565916.HKD","HELX","EKG","BK4551","GNMX","LU0109394709.USD","PTH","GH","FFOX","BK4588","BK4585","LU0320765992.SGD","BK4535","BK4196","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672548717","title":"Spyre Therapeutics Inc : Jonestrading Raises Target Price to $130 from $121","url":"https://stock-news.laohu8.com/highlight/detail?id=2672548717","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672548717?lang=en_us&edition=fundamental","pubTime":"2026-10-01 19:40","pubTimestamp":1790854836,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nFWN45N160:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LFSC","SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672983731","title":"Arovella Nears First Patient Dosing in Pivotal ALA-101 Cell Therapy Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2672983731","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672983731?lang=en_us&edition=fundamental","pubTime":"2026-10-01 12:18","pubTimestamp":1790828280,"startTime":"0","endTime":"0","summary":"Arovella Therapeutics Limited ( ($AU:ALA) ) has provided an announcement. Arovella Therapeutics is advancing an iNKT cell therapy platform aimed at...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/arovella-nears-first-patient-dosing-in-pivotal-ala-101-cell-therapy-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/arovella-nears-first-patient-dosing-in-pivotal-ala-101-cell-therapy-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LFSC","SYNB","TBXU","FBT","BK4585","LABX","ALA","IBBQ","CNCR","IBB","GNOM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671783151","title":"Spyre Therapeutics Shares up 6.4% After Merck's Experimental Drug Succeeds in Skin Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2671783151","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671783151?lang=en_us&edition=fundamental","pubTime":"2026-09-30 22:56","pubTimestamp":1790780218,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nFWN45M1BP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SYRE","BK4139","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671150783","title":"Spyre Gains After Merck's Drug Succeeds in Skin Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2671150783","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671150783?lang=en_us&edition=fundamental","pubTime":"2026-09-30 22:56","pubTimestamp":1790780215,"startTime":"0","endTime":"0","summary":"BUZZ-Spyre gains after Merck's drug succeeds in skin disease trial** Shares of Spyre TherapeuticsSYRE.Orise 6.08% to $89.87** Merck'sMRK.Nexperimental drug tulisokibartsignificantly reducesinflammator","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nL4N45M1CK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGXZ57979304.SGD","BK4550","LU1989772923.USD","SG9999001176.SGD","LU1291159041.SGD","RXL","LU0162691827.USD","LU1162221912.USD","LU1941712264.USD","LU1066051811.HKD","LU2324357040.USD","LU2357627491.SGD","LU1093756325.SGD","LU0265550359.USD","LU2361044865.SGD","BK4588","XLV","LU0985320562.USD","BK4516","PPH","LU2360032135.SGD","IE0002141913.USD","SG9999014567.USD","FTXH","LU2491049909.HKD","LU0965509101.SGD","LU1069347547.HKD","LFSC","VHT","IE0009355771.USD","LU2023250504.SGD","BK4585","LU0289739343.SGD","LU0823416689.USD","SG9999013999.USD","GDOC","LU0058720904.USD","IE00BLSP4452.SGD","LU0124676726.USD","LU0069063385.USD","BK4534","LU0072461881.USD","LU1057294990.SGD","BK4139","LU1585245621.USD","LU1061106388.HKD","SG9999014542.SGD","SG9999014575.USD","BK4559","LU2491050154.USD","LU2361045086.USD","LU0234572021.USD","LU1116320901.HKD","LU0861579265.USD","LU0106261372.USD","LU0070302665.USD","LU0203347892.USD","IE00BSNM7G36.USD","LU0208291251.USD","LU2433249047.HKD","SG9999014559.SGD","LU1032466523.USD","IE00BFTCPJ56.SGD","LU0266013472.USD","LU2125909247.SGD","BK4533","LU1035773651.USD","LU1093756168.USD","HRTS","LU0320765646.SGD","LU0689626769.HKD","LU0238689110.USD","LU1934455194.USD","LU1201861249.SGD","LU1430594728.SGD","SG9999001440.SGD","LU2468319806.SGD","LU0320765489.SGD","MRK","IE000M9KFDE8.USD","LU0289739699.SGD","LU0211331839.USD","LU1923622614.USD","LU1974910355.USD","LU0859254822.USD","LU0965508806.USD","LU1917777945.USD","LU0265550946.USD","IXJ","LU1934455277.USD","SG9999001176.USD","LU2125909593.SGD","LU2125154935.USD","LU0511384066.AUD","LU1571399168.USD","IE00BJT1NW94.SGD","TRUH","LU0648001328.SGD","SYRE","SG9999015341.SGD","LU0432979614.USD","LU0942090050.USD","IE00B2B36J28.USD","LU0130102774.USD","LU2125154778.USD","LU2023250843.SGD","IE00B1BXHZ80.USD","LU0980610538.SGD","LU2112291526.USD","LU0098860793.USD","LU1037948897.HKD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","LU1941712348.USD","PAWZ","LU0122379950.USD","IE00BBT3K403.USD","LU0057025933.USD","SG9999002232.USD","JDOC","LU2106854487.HKD","LU2089984988.USD","LU1934455863.HKD","LU1989771016.USD","LU2461242641.AUD","SG9999015358.SGD","BMED","LU0006306889.USD","LU0868494708.USD","SG9999002224.SGD","IYH","LU1066053197.SGD","LU1989772840.SGD","LU1037948541.HKD","LU0965509283.SGD","IE00BLSP4239.USD","LU0868494617.USD","IHE","LU1929549753.HKD","BK4007","IE00BN8TJ469.HKD","LU0472753341.HKD","LU1066051225.USD","LU2491050071.SGD","LU0130517989.USD","FHLC","LU1023059063.AUD","LU0965509010.AUD","LU1983299246.USD","LU0203345920.USD","LU1699723380.USD","LU0477156953.USD","LU2361044949.HKD","LU1066051498.USD","LU1116320737.USD","LU0289961442.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671520485","title":"MiNK selected for ARPA-H-Funded initiative to advance room-temp cell therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2671520485","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671520485?lang=en_us&edition=fundamental","pubTime":"2026-09-30 20:10","pubTimestamp":1790770233,"startTime":"0","endTime":"0","summary":"MiNK Therapeutics (INKT) announced that its clinical-stage agenT-797 iNKT platform has been selected as a therapeutic cell system within an Advance...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mink-selected-for-arpa-h-funded-initiative-to-advance-room-temp-cell-therapy-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mink-selected-for-arpa-h-funded-initiative-to-advance-room-temp-cell-therapy-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","IBBQ","INKT","IBB","LFSC","CNCR","FBT","BK4139","SYNB","BK4585","GNOM","TBXU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}]}}